Key Client Fiduciary Advisors LLC Cuts Holdings in Agenus Inc. (NASDAQ:AGEN)

Key Client Fiduciary Advisors LLC lowered its holdings in Agenus Inc. (NASDAQ:AGEN) by 91.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,754 shares of the biotechnology company’s stock after selling 789,215 shares during the quarter. Key Client Fiduciary Advisors LLC’s holdings in Agenus were worth $1,168,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. lifted its stake in Agenus by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock valued at $324,000 after acquiring an additional 13,604 shares during the period. PCG Wealth Advisors LLC raised its holdings in shares of Agenus by 65.7% during the fourth quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 18,850 shares during the last quarter. Crestline Management LP raised its holdings in shares of Agenus by 6.5% during the fourth quarter. Crestline Management LP now owns 708,480 shares of the biotechnology company’s stock valued at $587,000 after purchasing an additional 43,480 shares during the last quarter. Powell Investment Advisors LLC lifted its position in Agenus by 21.8% during the first quarter. Powell Investment Advisors LLC now owns 243,500 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 43,500 shares during the period. Finally, RPO LLC purchased a new stake in Agenus in the fourth quarter worth approximately $43,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Trading Down 2.8 %

Agenus stock traded down $0.13 during trading on Wednesday, reaching $4.58. The company had a trading volume of 650,288 shares, compared to its average volume of 742,897. The firm has a market capitalization of $96.18 million, a price-to-earnings ratio of -0.36 and a beta of 1.33. The firm’s 50-day simple moving average is $11.58 and its 200 day simple moving average is $11.89. Agenus Inc. has a 52 week low of $4.41 and a 52 week high of $32.00.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) EPS for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The firm had revenue of $23.51 million during the quarter, compared to analysts’ expectations of $64.73 million. During the same quarter in the prior year, the business earned ($4.00) earnings per share. On average, analysts predict that Agenus Inc. will post -10.73 earnings per share for the current year.

Analysts Set New Price Targets

AGEN has been the subject of a number of research reports. Jefferies Financial Group reiterated a “hold” rating and set a $7.00 target price (up from $3.00) on shares of Agenus in a research note on Friday, July 19th. William Blair downgraded Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. B. Riley dropped their target price on Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research report on Monday. Finally, Baird R W cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $10.50.

Agenus Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.